20 µg versus &gt;20 µg estrogen combined oral contraceptives for contraception (Q24243992)

Europe PubMed Central

title

20 µg versus >20 µg estrogen combined oral contraceptives for contraception (English)

0 references

0 references

2

Kavita Nanda

0 references

Laureen M Lopez

4

Laureen M Lopez

0 references

David Grimes

3

David A Grimes

0 references

Kenneth F Schulz

5

Kenneth F Schulz

0 references

Maria F Gallo

1

Cochrane Database of Systematic Reviews

Maria F Gallo

0 references

publication date

20 April 2005

0 references

published in

0 references

cites work

Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

Progestogens in combined oral contraceptives for contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Oral contraceptives and cycle control: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Low dose contraceptive formulations: is further reduction in steroid dosage justified?

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A randomized, double-blind study of six combined oral contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Metabolic effects of three new low-dose pills: a six-month experience

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Ovarian function during low-dose oral contraceptive use

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The effect of desogestrel, gestodene, and other factors on spotting and bleeding

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Changes in androgens during treatment with four low-dose contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Shorter pill-free interval in combined oral contraceptives decreases follicular development

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Twenty micrograms vs. >20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Optimum dosage of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, li

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effect of dienogest-containing oral contraceptives on lipid metabolism

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gyner

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Ovarian activity during regular oral contraceptive use

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized tri

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle contr

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Influence of hormonal contraceptives on microbial flora of gingival sulcus

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Effect of oral contraceptives containing 20 and 35 micrograms ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Allocation concealment in randomised trials: defending against deciphering

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

What contributions do languages other than English make on the results of meta-analyses?

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A prospective study evidencing rhinomanometric and olfactometric outcomes in women taking oral contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Direction and impact of language bias in meta-analyses of controlled trials: empirical study.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A randomized double-blind trial of two low dose combined oral contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Oral contraceptives and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Trends in the content and use of oral contraceptives in the United States, 1964-88

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021

A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003989.PUB2

7 January 2021